Novel Aromatic Amides Targeting FtsZ for Resistant Staphylococcal Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibacterial agents face challenges in effectively targeting resistant bacterial strains and maintaining pharmacokinetic stability, particularly for staphylococcal infections, where delivery and metabolic stability are crucial.
Innovation Solution
Development of novel aromatic amides that target FtsZ, incorporating a core modification with solubilizing and prodrug moieties, and a chiral center, enhancing metabolic stability and activity against resistant strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antibacterial agents are used to target bacterial infections, then some antibacterial activity is achieved, but they fail to effectively target resistant bacterial strains and maintain pharmacokinetic stability
Solution Approach 1:
The patent modifies the chemical structure of existing FtsZ-targeting compounds by introducing a core modification at the R3 position with various substituents (R4 groups). This structural parameter change enhances both the activity against resistant bacterial strains and the metabolic stability of the compound, resolving the contradiction between efficacy and stability.
Solution Approach 2:
The invention creates composite molecular structures by combining the core FtsZ-binding pharmacophore with additional functional moieties (solubilizing groups, prodrug moieties, and R4 substituents). This composite approach allows the molecule to simultaneously achieve improved pharmacokinetic properties, metabolic stability, and activity against resistant strains.
2Stability of the object's composition
If novel aromatic amides with core modifications are developed, then pharmacokinetic properties and metabolic stability are improved, but the molecular structure becomes more complex
Solution Approach 1:
The patent segments the molecular structure into distinct functional regions: a core FtsZ-binding pharmacophore, an R3 substituent position for metabolic stability, and R4 groups for additional properties. This segmentation allows systematic optimization of each region independently while maintaining overall molecular function, managing complexity through modular design.
Solution Approach 2:
The core modification at the R3 position serves multiple functions simultaneously: it provides metabolic stability, allows introduction of solubilizing moieties, enables prodrug functionality, and creates a chiral center. This multi-functionality reduces the need for separate modifications, managing molecular complexity while achieving multiple objectives.
3Reliability
If compounds with solubilizing and prodrug moieties are introduced, then pharmacokinetic properties are enhanced, but the synthesis and manufacturing process becomes more complex
Solution Approach 1:
The patent incorporates solubilizing and prodrug moieties directly into the core molecular structure during the primary synthesis phase, rather than adding them as post-synthesis modifications. This preliminary action simplifies the overall manufacturing process by integrating multiple functions into a single synthetic route, reducing the number of separate manufacturing steps required.
Data Source
AI summary
The present invention provides compounds of Formula (I): and salts, racemates, isomers, diastereoisomers, enantiomers, hydrates, solvates, N-oxides, pharmaceutically acceptable derivatives or prodrugs thereof. Also provided the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.